Perspective
Regulation of Follow-on Biologics
N Engl J Med 2007; 357:841-843August 30, 2007
- Article
Biopharmaceutical products, with U.S. sales in 2006 amounting to about $40.3 billion, are increasingly central to the treatment of major health problems affecting Americans.1 Since modern biopharmaceuticals date back to the 1980s, the first generation of such drugs has begun to lose patent protection (see table
Top-Selling Biopharmaceuticals Approved before 1993.). In other parts of the world, governments have crafted regulations defining the terms of competition from “imitator,” or generic, products. Many analysts have expressed concern that without new U.S. regulations, patent expirations may not be accompanied by the introduction of competing, lower-cost biologic agents — or that imitator products might be approved without sufficient proof of efficacy and safety, posing threats to public health. Although some biopharmaceutical products are nearly as simple as traditional small-molecule drugs, the vastly increased complexity of others means that it will be more difficult to ensure that an imitator product is biologically and functionally equivalent to the original. Because it may not be possible to create “true” generic versions of biopharmaceuticals, the term “follow-on biologic” is often used to refer to a new version of an existing biopharmaceutical that uses the same mechanism of action and treats the same clinical indications as the original.The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch–Waxman Act) offers a starting point for considering regulation of the use of follow-on biopharmaceuticals (see box
Key Provisions of the Hatch–Waxman Act.). This law, which is widely considered a success, governs the use of traditional generic medications. It establishes a low-cost path to market for generic imitators and requires their manufacturers to demonstrate bioequivalence but not to repeat human trials demonstrating efficacy and safety. The law also establishes minimum periods of market exclusivity for brand-name products.It took a number of years for the Hatch–Waxman Act to exert its full effect on prescription-drug prices. At first, many physicians were reluctant to view generic drugs as fully interchangeable with brand-name products. During the late 1980s, a brand-name drug generally lost about 15 to 30% of its sales volume in the first 2 years after its patent expired.2 In contrast, when Eli Lilly lost patent protection for the antidepressant drug Prozac (fluoxetine) in 2001, generic competitors garnered more than 70% of Prozac's market within 2 months.3 Today, brand-name drugs that face generic competition rapidly lose market share, and prices of generic products generally fall to 25 to 50% of the original brand-name prices.4 Although intense price competition reduces the financial returns for brand-name drugs, the patent period provides important protections, and the investment of U.S. drug companies in research and development has grown rapidly — from $26 billion in 2000 to about $43 billion in 2006.5
It was possible to achieve the benefits of the Hatch–Waxman Act because the Food and Drug Administration (FDA) could review data establishing bioequivalence and be confident that data on the safety and efficacy of the original drug would apply to generic versions as well. Biopharmaceuticals are frequently much more complex than small-molecule drugs, and their manufacture often entails the use of live cells and complicated biologic processes that are difficult to replicate. Indeed, the manufacturing process can be a trade secret. Thus, obtaining evidence that a drug is similar to and will have the same effects as the original is more complicated for biopharmaceuticals.
The European Union is ahead of the United States in dealing with these issues, although the FDA has begun to address them in an ad hoc fashion. Any U.S. policy in this arena will no doubt share some basic features with the one established in Europe. This means that a multistage process will probably be developed and that the FDA will be given a great deal of discretion in deciding how much data and testing are enough to establish attainment of the key standards of safety and efficacy — similarity and interchangeability — for follow-on biologics. Having such discretionary powers will also permit the FDA to incorporate rapidly changing technology into measurement and testing procedures.
The differences between follow-on biologics and generic pharmaceuticals suggest that market competition may also be very different. Bringing a product to market will be less certain and more costly for follow-on biologics than it is for generic drugs. The fixed costs of establishing a manufacturing plant are higher, and the variable manufacturing costs will be higher as well. In addition, biopharmaceutical production facilities must be scrutinized more closely than generic-drug manufacturing facilities. The uncertainty and costs of developing manufacturing capability and addressing the requirements of the regulatory process may reduce the number of firms seeking to produce follow-on biologics. An open question is whether there will be enough sellers to generate active price competition: economic research has generally shown that most of the benefits of price competition are not obtained until four or five firms enter a market. The expected profitability of developing a follow-on biologic will be paramount. The speed of entry will also depend on how much information about their manufacturing processes the makers of original biopharmaceuticals will be required to report. Analysts predict that more complicated molecules will have less competition from follow-on products, which will enter the market more slowly than traditional generic pharmaceuticals.
Finally, the returns to research and development for biopharmaceuticals are unclear. Suppose, as has been suggested, that regulations governing the approval of follow-on biologics guarantee 12 years of exclusivity for brand-name biopharmaceuticals and that the technological and economic environment dampens potential competition. These factors would create a favorable climate for investment in research and development, weakening the case for special provisions. On the other hand, it appears that the costs and risks associated with developing biopharmaceuticals exceed those for small-molecule drugs. So the net effect on expected returns on investment remains an open question. The years of exclusivity granted to brand-name products will probably be an important driver of these returns and pose a barrier to competition from follow-ons. It is premature to assume that 12 years of exclusivity will be needed to preserve innovation in the biopharmaceutical arena — and putting off price competition is risky because of pressures on public budgets and the expanded role of the Medicare program in purchasing biopharmaceuticals.
The prospect of the loss of patent protection for tens of billions of dollars' worth of biopharmaceuticals increases the urgency of the need for a regulatory policy that promotes price competition and preserves the safety and efficacy standards that Americans expect from prescription drugs. In my opinion, the Hatch–Waxman framework is not sufficient to cover both relatively simple biopharmaceuticals and very large and complex molecules — a new regulatory framework is needed. Because of the need for complex, situation-specific judgments, the FDA should be granted a great deal of discretion. The conflicting goals of bolstering price competition in biopharmaceutical markets and preserving the incentives for innovation call for a nuanced policy that must be based on the best current science and key features of the economics of biopharmaceutical markets — not on the impassioned claims of the interested parties.
An interview with Senator Orrin Hatch (R-UT) can be heard at www.nejm.org.
Source Information
Dr. Frank is a professor of health economics at Harvard Medical School, Boston.
- References
References
1
IMS Health. IMS reports U.S. prescription sales jump 8.3 percent in 2006, to $274.9 billion. (Accessed August 9, 2007, at http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_80415465,00.html.)
2
Office of Technology Assessment. Pharmaceutical R&D: costs, risks, and rewards. Washington, DC: Government Printing Office, February 1993.
3
Carey S. Lilly reports 22% decline in net as generics hurt sales of Prozac. Wall Street Journal. April 30, 2002.
4
Reiffen D ,Ward MR . Generic drug industry dynamics. Rev Econ Stat 2005;87:37-49
CrossRef | Web of Science5
Pharmaceutical Research and Manufacturers of America. Pharmaceutical indus-try profile 2007. Washington DC: PhRMA, 2007.
- Citing Articles (15)
Citing Articles
1
Marc Cohen, Walter P. Jeske, Jose C. Nicolau, Gilles Montalescot, Jawed Fareed. (2012) US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. Journal of Thrombosis and Thrombolysis
CrossRef2
Paul Saenger. (2012) Biosimilar Growth Hormone. The Indian Journal of Pediatrics 79:1, 92-98
CrossRef3
F. A. Ofosu. (2012) A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Thrombosis and Haemostasis 107:2,
CrossRef4
AARON S. KESSELHEIM. (2011) An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences. Milbank Quarterly 89:3, 450-502
CrossRef5
David R. Holmes, Jeffrey A. Becker, Christopher B. Granger, Marian C. Limacher, Robert Lee Page, Cathy Sila, Joseph P. Drozda, Joseph G. Cacchione, Blair D. Erb, Robert A. Harrington, Jerry D. Kennett, Harlan M. Krumholz, Frederick A. Masoudi, Eric D. Peterson, Athena Poppas, David J. Sahn, Mark L. Sanz, David M. Shahian, John R. Windle, Janet F. Wyman. (2011) ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution. Journal of the American College of Cardiology 58:12, 1287-1307
CrossRef6
2011. References. , 553-576.
CrossRef7
Michael Orme, Folke Sjöqvist, Donald Birkett, Kim Brøsen, Ingolf Cascorbi, Lars L Gustafsson, Simon Maxwell, Lembit Rago, Michael Rawlins, Marcus Reidenberg, Folke Sjöqvist, Tony Smith, Petra Thuerman, Andrew Walubo. (2010) Clinical Pharmacology in Research, Teaching and Health Care. Basic & Clinical Pharmacology & Toxicology 107:1, 531-559
CrossRef8
Igor A. Kaltashov, Cedric E. Bobst, Rinat R. Abzalimov, Steven A. Berkowitz, Damian Houde. (2010) Conformation and dynamics of biopharmaceuticals: Transition of mass spectrometry-based tools from academe to industry. Journal of the American Society for Mass Spectrometry 21:3, 323-337
CrossRef9
Thijs J. Giezen, Aukje K. Mantel-Teeuwisse, Hubert G.M. Leufkens. (2009) Pharmacovigilance of Biopharmaceuticals. Drug Safety 32:10, 811-817
CrossRef10
Sai R Keithi-Reddy, Ajay K Singh. (2009) Response to ‘Not all new recombinant human erythropoietins are biosimilars’. Kidney International 75:4, 441-442
CrossRef11
Dil M. Ramanathan, Richard M. Lelacheur. 2008. Evolving Role of Mass Spectrometry in Drug Discovery and Development. , 1-85.
CrossRef12
J.M. Wit, E.O. Reiter, J.L. Ross, P.H. Saenger, M.O. Savage, A.D. Rogol, P. Cohen. (2008) Idiopathic short stature: Management and growth hormone treatment. Growth Hormone & IGF Research 18:2, 111-135
CrossRef13
Dudzinski, David M., Kesselheim, Aaron S., . (2008) Scientific and Legal Viability of Follow-on Protein Drugs. New England Journal of Medicine 358:8, 843-849
Full Text14
(2008) Bibliography. Biotechnology Law Report 27:1, 24-24
CrossRef15
Saurabh Aggarwal. (2007) What's fueling the biotech engine?. Nature Biotechnology 25:10, 1097-1104
CrossRef
